BofA analyst Kevin Fischbeck upgraded Elevance Health (ELV) to Buy from Neutral with a price target of $435, up from $425.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $411 from $397 at JPMorgan
- Elevance Health price target raised to $399 from $396 at Guggenheim
- Elevance Health price target raised to $408 from $393 at Barclays
- Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
- Elevance Health price target raised to $364 from $357 at Leerink